Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
40
ICUI Quote, Financials, Valuation and Earnings
Last price:
$149.48
Seasonality move
:
4.64%
Day range:
$141.22 - $149.99
52-week range:
$93.36 - $196.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.53x
P/B ratio:
1.86x
Volume:
208.6K
Avg. volume:
249.3K
1-year change:
52.13%
Market cap:
$3.7B
Revenue:
$2.4B
EPS (TTM):
-$4.83
Analysts' Opinion
-
Consensus RatingICU Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $190.00, ICU Medical has an estimated upside of 27.34% from its current price of $149.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $178.00 representing 100% downside risk from its current price of $149.21.
Fair Value
-
According to the consensus of 4 analysts, ICU Medical has 27.34% upside to fair value with a price target of $190.00 per share.
ICUI vs. S&P 500
-
Over the past 5 trading days, ICU Medical has overperformed the S&P 500 by 13.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ICU Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ICU Medical has grown year-over-year revenues for 3 quarters straight. In the most recent quarter ICU Medical reported revenues of $629.8M.
Earnings Growth
-
ICU Medical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ICU Medical reported earnings per share of -$0.97.
Enterprise value:
4.9B
EV / Invested capital:
1.39x
Price / LTM sales:
1.53x
EV / EBIT:
121.71x
EV / Revenue:
2.07x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
43.33x
Price / Operating cash flow:
31.97x
Enterprise value / EBITDA:
18.97x
Gross Profit (TTM):
$824.8M
Return On Assets:
-2.74%
Net Income Margin (TTM):
-4.94%
Return On Equity:
-5.75%
Return On Invested Capital:
-3.22%
Operating Margin:
7.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.3B | $2.3B | $2.4B | $587.9M | $629.8M | |
| Gross Profit | $697.8M | $739.9M | $824.8M | $171.6M | $227.3M | |
| Operating Income | -$3.6M | $47.8M | $97.4M | -$5.4M | $46.1M | |
| EBITDA | $191.5M | $253.2M | $260M | $47.2M | $87.4M | |
| Diluted EPS | -$3.12 | -$1.23 | -$4.83 | -$0.71 | -$0.97 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $920.8M | $1B | $1.2B | $1.2B | $1.4B | |
| Total Assets | $1.8B | $1.9B | $4.5B | $4.4B | $4.2B | |
| Current Liabilities | $195.5M | $200.8M | $494.6M | $481.8M | $556.2M | |
| Total Liabilities | $261.4M | $264.7M | $2.4B | $2.3B | $2.2B | |
| Total Equity | $1.5B | $1.6B | $2.1B | $2.1B | $2B | |
| Total Debt | -- | -- | $1.7B | $1.6B | $1.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.1M | $166.2M | $204M | $91.3M | $40.2M | |
| Cash From Investing | -$1.9B | -$87.9M | -$89M | -$30.7M | -$26.5M | |
| Cash From Financing | $1.6B | -$36M | -$55.8M | -$7.8M | -$8.2M | |
| Free Cash Flow | -$161.5M | $72.5M | $113.8M | $59.3M | $13.6M | |
ICUI
Sector
Market Cap
$3.7B
$37.4M
Price % of 52-Week High
76.02%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
52.13%
-38.36%
Beta (5-Year)
0.733
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$142.62
200-day SMA
Sell
Level
$152.73
Bollinger Bands (100)
Sell
Level
152.01 - 172.51
Chaikin Money Flow
Buy
Level
8.8M
20-day SMA
Sell
Level
$149.68
Relative Strength Index (RSI14)
Buy
Level
50.06
ADX Line
Sell
Level
34.29
Williams %R
Neutral
Level
-28.9885
50-day SMA
Sell
Level
$157.28
MACD (12, 26)
Sell
Level
-4.65
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
28.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1007)
Sell
CA Score
(Annual)
Level (-0.3132)
Buy
Beneish M-Score
(Annual)
Level (-2.8084)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.4451)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Stock Forecast FAQ
In the current month, ICUI has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ICUI average analyst price target in the past 3 months is $190.00.
-
Where Will ICU Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that ICU Medical share price will rise to $190.00 per share over the next 12 months.
-
What Do Analysts Say About ICU Medical?
Analysts are divided on their view about ICU Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ICU Medical is a Sell and believe this share price will drop from its current level to $178.00.
-
What Is ICU Medical's Price Target?
The price target for ICU Medical over the next 1-year time period is forecast to be $190.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ICUI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ICU Medical is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ICUI?
You can purchase shares of ICU Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ICU Medical shares.
-
What Is The ICU Medical Share Price Today?
ICU Medical was last trading at $149.48 per share. This represents the most recent stock quote for ICU Medical. Yesterday, ICU Medical closed at $149.21 per share.
-
How To Buy ICU Medical Stock Online?
In order to purchase ICU Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
Sell
47
CELH alert for Mar 18
Celsius Holdings [CELH] is up 1.44% over the past day.
